| 1 |
ccssid
[numeric] |
Mean (sd) : 14350952.7 (7820285.7)
min < med < max:
1000057 < 15169015 < 29454734
IQR (CV) : 12272700 (0.5) |
7891 distinct values |
 |
0
(0%) |
| 2 |
status
[factor] |
1. Normal
2. PM
3. AOF
4. Surgical PM
5. AOF-no menarche
6. PM (possible) |
| 6659 | ( | 84.4% | ) | | 413 | ( | 5.2% | ) | | 187 | ( | 2.4% | ) | | 285 | ( | 3.6% | ) | | 344 | ( | 4.4% | ) | | 3 | ( | 0.0% | ) |
|
 |
0
(0%) |
| 3 |
a_event
[numeric] |
Mean (sd) : 31.9 (8.9)
min < med < max:
9.9 < 32 < 57
IQR (CV) : 13.2 (0.3) |
3979 distinct values |
 |
38
(0.48%) |
| 4 |
cohort
[factor] |
1. Original
2. Expansion |
|
 |
0
(0%) |
| 5 |
diagnose
[factor] |
1. Leukemia
2. CNS
3. HD
4. HNL
5. Kidney (Wilms)
6. Neuroblastoma
7. Soft tissue sarcoma
8. Bone cancer |
| 2589 | ( | 32.8% | ) | | 767 | ( | 9.7% | ) | | 1182 | ( | 15.0% | ) | | 527 | ( | 6.7% | ) | | 948 | ( | 12.0% | ) | | 643 | ( | 8.2% | ) | | 453 | ( | 5.7% | ) | | 782 | ( | 9.9% | ) |
|
 |
0
(0%) |
| 6 |
age_dx
[numeric] |
Mean (sd) : 8.6 (5.9)
min < med < max:
0 < 7.5 < 21
IQR (CV) : 10.5 (0.7) |
5639 distinct values |
 |
0
(0%) |
| 7 |
d_dx
[Date] |
min : 1970-01-05
med : 1985-05-28
max : 1999-12-30
range : 29y 11m 25d |
4924 distinct values |
 |
0
(0%) |
| 8 |
d_birth
[Date] |
min : 1949-09-12
med : 1977-12-30
max : 1998-08-25
range : 48y 11m 13d |
5893 distinct values |
 |
0
(0%) |
| 9 |
excl_b4_cutage
[character] |
1. exclude(when cutoff age>a
2. exclude(when cutoff age>a |
|
 |
7762
(98.37%) |
| 10 |
age_algorithms
[character] |
1. norm1
2. norm2
3. nspm
4. aof2
5. spm1
6. norm4
7. aof1_1
8. spm2
9. spm1_2
10. aof1_2
[ 2 others ] |
| 4714 | ( | 59.9% | ) | | 1564 | ( | 19.9% | ) | | 376 | ( | 4.8% | ) | | 344 | ( | 4.4% | ) | | 274 | ( | 3.5% | ) | | 248 | ( | 3.1% | ) | | 165 | ( | 2.1% | ) | | 126 | ( | 1.6% | ) | | 42 | ( | 0.5% | ) | | 17 | ( | 0.2% | ) | | 6 | ( | 0.1% | ) |
|
 |
15
(0.19%) |
| 11 |
bmt_yn
[factor] |
1. No
2. Yes |
|
 |
6
(0.08%) |
| 12 |
bmt_tbi
[factor] |
1. No
2. Yes |
|
 |
619
(7.84%) |
| 13 |
rt_yn
[factor] |
1. No
2. Yes |
|
 |
474
(6.01%) |
| 14 |
tbirt_yn
[factor] |
1. No
2. Yes |
|
 |
641
(8.12%) |
| 15 |
abdomenrt_yn
[factor] |
1. No
2. Yes |
|
 |
641
(8.12%) |
| 16 |
abdomen_nontbi
[factor] |
1. No
2. Yes |
|
 |
641
(8.12%) |
| 17 |
pelvisrt_yn
[factor] |
1. No
2. Yes |
|
 |
640
(8.11%) |
| 18 |
pelvis_nontbi
[factor] |
1. No
2. Yes |
|
 |
640
(8.11%) |
| 19 |
tbidose
[integer] |
Mean (sd) : 26.9 (180.7)
min < med < max:
0 < 0 < 1575
IQR (CV) : 0 (6.7) |
23 distinct values |
 |
644
(8.16%) |
| 20 |
abdmaxrtdose
[integer] |
Mean (sd) : 534.3 (1107.9)
min < med < max:
0 < 0 < 6900
IQR (CV) : 200 (2.1) |
89 distinct values |
 |
649
(8.22%) |
| 21 |
pelvismaxrtdose
[integer] |
Mean (sd) : 420.8 (1060.6)
min < med < max:
0 < 0 < 7800
IQR (CV) : 20 (2.5) |
88 distinct values |
 |
648
(8.21%) |
| 22 |
pitdose
[numeric] |
Mean (sd) : 391.2 (791.9)
min < med < max:
0 < 0 < 2940
IQR (CV) : 110 (2) |
414 distinct values |
 |
675
(8.55%) |
| 23 |
minovary
[numeric] |
Mean (sd) : 155.6 (546.3)
min < med < max:
0 < 0 < 5940
IQR (CV) : 13 (3.5) |
446 distinct values |
 |
709
(8.98%) |
| 24 |
maxovary
[numeric] |
Mean (sd) : 194.2 (681.2)
min < med < max:
0 < 0 < 7800
IQR (CV) : 14 (3.5) |
484 distinct values |
 |
715
(9.06%) |
| 25 |
ced5
[numeric] |
Mean (sd) : 4352 (7189.4)
min < med < max:
0 < 0 < 83301.3
IQR (CV) : 6977.5 (1.7) |
2971 distinct values |
 |
990
(12.55%) |
| 26 |
bcnu_yn
[factor] |
1. No
2. Yes |
|
 |
479
(6.07%) |
| 27 |
busulfan_yn
[factor] |
1. No
2. Yes |
|
 |
480
(6.08%) |
| 28 |
ccnu_yn
[factor] |
1. No
2. Yes |
|
 |
478
(6.06%) |
| 29 |
chlorambucil_yn
[factor] |
1. No
2. Yes |
|
 |
478
(6.06%) |
| 30 |
cyclophosphamide_yn
[factor] |
1. No
2. Yes |
|
 |
501
(6.35%) |
| 31 |
ifosfamide_yn
[factor] |
1. No
2. Yes |
|
 |
481
(6.1%) |
| 32 |
melphalan_yn
[factor] |
1. No
2. Yes |
|
 |
481
(6.1%) |
| 33 |
nitrogen_mustard_yn
[factor] |
1. No
2. Yes |
|
 |
483
(6.12%) |
| 34 |
procarbazine_yn
[factor] |
1. No
2. Yes |
|
 |
485
(6.15%) |
| 35 |
thiotepa_yn
[factor] |
1. No
2. Yes |
|
 |
480
(6.08%) |
| 36 |
carboplatin_yn
[factor] |
1. No
2. Yes |
|
 |
480
(6.08%) |
| 37 |
cis_platinum_yn
[factor] |
1. No
2. Yes |
|
 |
480
(6.08%) |
| 38 |
bleomycin_yn
[factor] |
1. No
2. Yes |
|
 |
485
(6.15%) |
| 39 |
daunorubicin_yn
[factor] |
1. No
2. Yes |
|
 |
484
(6.13%) |
| 40 |
doxorubicin_yn
[factor] |
1. No
2. Yes |
|
 |
492
(6.23%) |
| 41 |
epirubicin_yn
[factor] |
1. No
2. Yes |
|
 |
478
(6.06%) |
| 42 |
idarubicin_yn
[factor] |
1. No
2. Yes |
|
 |
478
(6.06%) |
| 43 |
methotrexate_yn
[factor] |
1. No
2. Yes |
|
 |
493
(6.25%) |
| 44 |
mitoxantrone_yn
[factor] |
1. No
2. Yes |
|
 |
479
(6.07%) |
| 45 |
vm_26_yn
[factor] |
1. No
2. Yes |
|
 |
481
(6.1%) |
| 46 |
vp_16_yn
[factor] |
1. No
2. Yes |
|
 |
486
(6.16%) |
| 47 |
bcnu
[numeric] |
Mean (sd) : 8 (68.2)
min < med < max:
0 < 0 < 1573.3
IQR (CV) : 0 (8.5) |
127 distinct values |
 |
491
(6.22%) |
| 48 |
busulfan
[numeric] |
Mean (sd) : 3 (37.3)
min < med < max:
0 < 0 < 650.4
IQR (CV) : 0 (12.3) |
60 distinct values |
 |
491
(6.22%) |
| 49 |
ccnu
[numeric] |
Mean (sd) : 3.6 (45.4)
min < med < max:
0 < 0 < 1333.3
IQR (CV) : 0 (12.7) |
61 distinct values |
 |
492
(6.23%) |
| 50 |
chlorambucil
[numeric] |
Mean (sd) : 1.6 (57.2)
min < med < max:
0 < 0 < 3349.5
IQR (CV) : 0 (34.8) |
17 distinct values |
 |
484
(6.13%) |
| 51 |
cyclophosphamide
[numeric] |
Mean (sd) : 2937.5 (5485.3)
min < med < max:
0 < 0 < 83301.3
IQR (CV) : 4171.7 (1.9) |
2529 distinct values |
 |
820
(10.39%) |
| 52 |
ifosfamide
[numeric] |
Mean (sd) : 1874.3 (10460.2)
min < med < max:
0 < 0 < 144229.8
IQR (CV) : 0 (5.6) |
318 distinct values |
 |
502
(6.36%) |
| 53 |
melphalan
[numeric] |
Mean (sd) : 1.6 (19.1)
min < med < max:
0 < 0 < 514.3
IQR (CV) : 0 (11.7) |
77 distinct values |
 |
488
(6.18%) |
| 54 |
nitrogen_mustard
[numeric] |
Mean (sd) : 2.1 (11.1)
min < med < max:
0 < 0 < 256.9
IQR (CV) : 0 (5.3) |
293 distinct values |
 |
530
(6.72%) |
| 55 |
procarbazine
[numeric] |
Mean (sd) : 379.7 (1462.9)
min < med < max:
0 < 0 < 17500
IQR (CV) : 0 (3.9) |
531 distinct values |
 |
603
(7.64%) |
| 56 |
thiotepa
[numeric] |
Mean (sd) : 1.7 (33.6)
min < med < max:
0 < 0 < 934
IQR (CV) : 0 (19.3) |
25 distinct values |
 |
487
(6.17%) |
| 57 |
carboplatin
[numeric] |
Mean (sd) : 55.3 (525.9)
min < med < max:
0 < 0 < 15711.1
IQR (CV) : 0 (9.5) |
126 distinct values |
 |
501
(6.35%) |
| 58 |
cis_platinum
[numeric] |
Mean (sd) : 29.4 (163)
min < med < max:
0 < 0 < 7075.1
IQR (CV) : 0 (5.5) |
422 distinct values |
 |
522
(6.62%) |
| 59 |
bleomycin
[numeric] |
Mean (sd) : 5.8 (23.5)
min < med < max:
0 < 0 < 402.5
IQR (CV) : 0 (4) |
456 distinct values |
 |
526
(6.67%) |
| 60 |
daunorubicin
[numeric] |
Mean (sd) : 27.4 (81.2)
min < med < max:
0 < 0 < 839
IQR (CV) : 0 (3) |
867 distinct values |
 |
543
(6.88%) |
| 61 |
doxorubicin
[numeric] |
Mean (sd) : 90.3 (144)
min < med < max:
0 < 0 < 1070
IQR (CV) : 156.2 (1.6) |
2181 distinct values |
 |
700
(8.87%) |
| 62 |
epirubicin
[numeric] |
1 distinct value |
|
 |
478
(6.06%) |
| 63 |
idarubicin
[numeric] |
Mean (sd) : 0.4 (5.5)
min < med < max:
0 < 0 < 192.7
IQR (CV) : 0 (14.8) |
54 distinct values |
 |
479
(6.07%) |
| 64 |
methotrexate
[numeric] |
Mean (sd) : 6823.7 (32448.9)
min < med < max:
0 < 0 < 502553.5
IQR (CV) : 223.7 (4.8) |
2434 distinct values |
 |
761
(9.64%) |
| 65 |
mitoxantrone
[numeric] |
Mean (sd) : 0.2 (3.2)
min < med < max:
0 < 0 < 96.9
IQR (CV) : 0 (17.4) |
28 distinct values |
 |
485
(6.15%) |
| 66 |
vm_26
[numeric] |
Mean (sd) : 108.1 (687.1)
min < med < max:
0 < 0 < 9300
IQR (CV) : 0 (6.4) |
283 distinct values |
 |
500
(6.34%) |
| 67 |
vp_16
[numeric] |
Mean (sd) : 480.8 (1871.1)
min < med < max:
0 < 0 < 20594
IQR (CV) : 0 (3.9) |
881 distinct values |
 |
568
(7.2%) |
| 68 |
race_5
[factor] |
1. white
2. Black
3. America native
4. Asian or Pacific Islander
5. Other |
| 6795 | ( | 87.1% | ) | | 483 | ( | 6.2% | ) | | 39 | ( | 0.5% | ) | | 117 | ( | 1.5% | ) | | 367 | ( | 4.7% | ) |
|
 |
90
(1.14%) |
| 69 |
race_3
[factor] |
1. white
2. Black
3. Other |
| 6795 | ( | 87.1% | ) | | 483 | ( | 6.2% | ) | | 523 | ( | 6.7% | ) |
|
 |
90
(1.14%) |
| 70 |
smoke_100
[factor] |
1. No
2. Yes |
|
 |
351
(4.45%) |